Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Health Care Activity > Tissue Procurement

Tissue Procurement

Tissue Procurement refers to the process of obtaining biological tissues from donors or sources for use in research, medical procedures, or other applications.
This process involves careful selection, collection, and handling of tissue samples to ensure their quality, integrity, and suitability for the intended use.
Tissue Procurement may include the acquisition of human tissues, animal tissues, or plant materials, and it is a critical step in maintaining the reproducibility and accuracy of research involving biological samples.
The process is guided by ethical guidelines, regulatory requirements, and best practices to protect the donors, minimize waste, and maximize the utility of the procured tissues.

Most cited protocols related to «Tissue Procurement»

1
Quantitative Imaging of Tissues via IR-MALDESI
All experiments mentioned in this manuscript were performed in accordance with local ethical guidelines. Human cervical tissues were obtained from the University of North Carolina Tissue Procurement Facility through UNC IRB #09-0921, and written informed consent was obtained from all patients. Two-day-old whole neonatal mouse pups were obtained from NCSU Department of Molecular Biomedical Sciences. Hen ovarian tissues were acquired from commercial egg laying hens in the NCSU Department of Poultry Science. All husbandry practices were approved by North Carolina State University Institutional Animal Care and Use Committee (IACUC).
All imaging experiments were performed in our laboratory using infrared matrix-assisted laser desorption electrospray ionization (IR-MALDESI) sourced coupled to high resolving power mass spectrometers. The details of IR-MALDESI source design and steps involved in imaging experiments are described elsewhere in detail [10 (link), 17 (link), 18 ]. In short, the tissues were sectioned into 10–25 μm thick sections using a Leica CM1950 cryostat (Buffalo Grove, IL, USA) and then thaw-mounted onto clean microscope slides. For quantitative MSI analyses, a calibration series of stable isotope labeled version of the analyte was pipetted directly on top of the tissue section prior to IR-MALDESI analysis. The tissue sections were then transferred to the enclosure housing the IR-MALDESI imaging source and placed on a Peltier-cooled stage. The relative humidity inside the enclosure was reduced to ~10% by purging the enclosure with dry nitrogen gas, and the stage temperature was reduced to -10 °C. After roughly 10 minutes, the enclosure was opened to allow the deposition of a thin layer of ice matrix on the tissue by sublimation of water present in the atmosphere. Once a thin layer of ice was formed over the tissue, the enclosure was closed and the relative humidity was again reduced to ~10%.
Two mid-infrared laser pulses at a wavelength of 2940 nm were used to desorb material from the tissue sections. The neutral material desorbed from the tissue partition into the charged droplets of the electrospray and are ionized in an ESI-like fashion. Quantitative MSI and whole-body MSI were performed using a Q Exactive mass spectrometer (Thermo Scientific, Bremen, Germany) as described by Bokhart et al. [19 (link)] and Rosen et al. [20 (link)], respectively. Polarity switching IR-MALDESI MSI was performed using a Q Exactive Plus mass spectrometer (Thermo Scientific, Bremen, Germany) as outlined by Nazari and Muddiman [21 (link)]. Since IR-MALDESI is a pulsed ionization source, the automatic gain control (AGC) is disabled and ions are stored in the C-trap for a pre-determined amount of time denoted by the maximum injection time (IT). Mass ranges, electrospray solvent composition, and the injection times varied for each experiment since these need to be optimized based on the goals of each analysis.
The .RAW files generated by the Thermo instruments were first converted to mzML format using the msConvert tool from ProteoWizard [22 (link)], and then converted to imzML using the imzML converter [23 (link)]. The imzML files were subsequently loaded into MSiReader v1.0 for visualization and analysis.
Bokhart M.T., Nazari M., Garrard K.P, & Muddiman D.C. (2017). MSiReader v1.0: Evolving Open-Source Mass Spectrometry Imaging Software for Targeted and Untargeted Analyses. Journal of the American Society for Mass Spectrometry, 29(1), 8-16.
Publication 2017
Atmosphere Buffaloes Fowls, Domestic Homo sapiens Human Body Humidity Infant, Newborn Institutional Animal Care and Use Committees Ions Isotopes Microscopy Mus Neck Nitrogen Ovary Patients Solvents Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Tissue Procurement Tissues
2
GTEx Biospecimen Collection Infrastructure
To meet the challenging biospecimen requirements of the GTEx pilot study, NCI's BBRB and its partners developed a novel infrastructure for collecting normal human biospecimens for research purposes. BBRB, together with the Frederick National Laboratory for Cancer Research, developed an operational plan to contract medical centers and OPOs to screen potential donors, consent next-of-kin, and collect and ship biospecimens. Each BSS complied with their respective institution's biospecimen handling policies to procure GTEx biospecimens that were sent to a central, separately contracted Comprehensive Biospecimen Resource (CBR).
The CBR inventoried and divided biospecimens for three purposes: (1) shipment to the separately contracted GTEx Laboratory, Data Analysis, and Coordinating Center (LDACC) for molecular analysis, (2) histology for pathology review, and (3) local storage for future analysis. Whole brains were sent directly from the BSSs to a separate Brain Bank for proper sectioning and were then subsequently sent to the LDACC for analysis. Also, blood and skin samples were sent directly to the LDACC to generate EBV-transformed lymphoblastoid cell lines and fibroblasts, respectively.
The entire biospecimen collection, processing, storage, and transfer operation was coordinated through a central quality control program and uses a custom web portal for data entry. A Pathology Resource Center (PRC), comprised of board-certified pathologists, evaluated the quality of the biospecimens. Figure 2 outlines the biospecimen platform and the flow of biospecimens and data to and from each site within the infrastructure. Detailed SOPs can be found at http://biospecimens.cancer.gov/resources/sops/library.asp that describe tissue procurement, shipping, kit utilization, data entry, pathology review, and other aspects of the GTEx project.
Carithers L.J., Ardlie K., Barcus M., Branton P.A., Britton A., Buia S.A., Compton C.C., DeLuca D.S., Peter-Demchok J., Gelfand E.T., Guan P., Korzeniewski G.E., Lockhart N.C., Rabiner C.A., Rao A.K., Robinson K.L., Roche N.V., Sawyer S.J., Segrè A.V., Shive C.E., Smith A.M., Sobin L.H., Undale A.H., Valentino K.M., Vaught J., Young T.R, & Moore H.M. (2015). A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project. Biopreservation and Biobanking, 13(5), 311-319.
Publication 2015
Barber Say syndrome BLOOD Brain cDNA Library Cell Line, Transformed Donors Fibroblasts Homo sapiens Malignant Neoplasms Pathologists Skin Tissue Procurement
3
Breast Cancer Molecular Subtypes Analysis
The training set contained a total of 357 formalin-fixed paraffin-embedded tissues from invasive breast carcinomas from the University of British Columbia and Washington University at St Louis (hereafter referred to as the UBC-WashU series). This series was chosen to include high- and low-risk patient groups, so that each of the major intrinsic breast cancer subtypes was represented by adequate numbers of specimens. In the combined cohort of 357 tumors, 137 (38%) were from patients with lymph node–positive disease, 200 (56%) were larger than 2 cm in diameter, and 133 (37%) were grade 3 by the Bloom and Richardson method (23 (link)) (see Table 1).
The validation set contained a total of 4046 formalin-fixed paraffin-embedded tissues. All patients had been referred to the British Columbia Cancer Agency from January 1, 1986, through September 30, 1992, and had staging, pathology, treatment, and follow-up information available (see Table 1); this cohort is hereafter referred to as the BCCA series. The median follow-up time was 12.5 years. In British Columbia, most patients were treated with adjuvant systemic therapy according to provincial cancer management guidelines set by the British Columbia Cancer Agency (24 (link)). The guidelines provided criteria for defining high-risk patients who could benefit from adjuvant systemic therapy. A high-risk patient was defined as being lymph node positive, having lymphovascular invasion, or having a tumor larger than 2 cm in diameter if it was also ER negative. Patients who were considered to be at clinically low risk at the time of diagnosis during the study era, which included approximately 40% of the study cohort, were not recommended to receive any adjuvant systemic therapy. Patients who were considered to be at high risk were recommended to receive tamoxifen if their tumor was ER positive and if they were older than 65 years, to receive chemotherapy if their tumor was ER negative or if they were younger than 50 years, and to receive both if their tumor was ER positive and if they were between ages 50 and 65 years.
Biomarker studies on the anonymized archival specimens and clinical data were approved by the Clinical Research Ethics Board of the British Columbia Cancer Agency and the Human Research Protection Office of Washington University. Tissues were collected according to institutional review board–approved protocols of the Alvin J. Siteman Cancer Center Tissue Procurement Core and at the British Columbia Cancer Agency.
In the BCCA series of 4046 breast tumors, a total of 2847 tumors were hormone receptor positive, of which 2598 had complete immunohistochemistry data for ER, PR, HER2, and Ki67 (see Table 1). We found no statistically significant differences in age, tumor size, lymph node status, or adjuvant systemic therapy between patients with complete immunohistochemistry data and patients with missing data; however, the missing data status was associated with less lymphovascular invasion (P = .010) and with a marginal tendency for lower grade (grade 1 or 2 vs grade 3) (P = .048) compared with the complete data available status.
Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., Watson M., Davies S., Bernard P.S., Parker J.S., Perou C.M., Ellis M.J, & Nielsen T.O. (2009). Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. JNCI Journal of the National Cancer Institute, 101(10), 736-750.
Publication 2009
Biological Markers Breast Carcinoma Breast Neoplasm Diagnosis ERBB2 protein, human Ethics Committees, Research Formalin Homo sapiens Hormones Immunohistochemistry Lymphatic Diseases Malignant Neoplasm of Breast Malignant Neoplasms Neoplasms Nodes, Lymph Paraffin Embedding Patients Pharmaceutical Adjuvants Pharmacotherapy Population at Risk Tamoxifen Therapeutics Tissue Procurement Tissues Youth
4
Purification of Resting Macrophage Subsets
All cells were purified using the sorting protocol and antibodies listed on http://www.immgen.org. Cells were directly sorted from mouse tissues and were processed from tissue procurement to a second round of sorting into Trizol within 4 h using a Beckton-Dickinson Aria II instrument. Resting red pulp macrophages from the spleen were sorted after nonenzymatic disaggregation of the spleen and were identified as F4/80hi cells that lacked B220 and high levels of CD11c and MHC II34 (link),35 (link); macrophages from the resting peritoneum were collected in a peritoneal lavage and stained to identify CD115hi cells that were F4/80hi MHC II−; resting pulmonary macrophages were isolated from Liberase III-digested lungs (15 min. digest) and macrophages were identified as SiglecF+ CD11c+ cells with low levels of MHC II26 (link),27 (link); and resting brain microglial macrophages were sorted from Liberase III-digested, Percoll-gradient separated cells that were CD11b+ CD45lo F4/80lo11 (link). The Data Browser in the Immgen website is a resource for pdf files showing FACS dot plots that depict the purification strategies and purity after isolation of these and all other populations. A list of abbreviations used in the Immgen database relevant to macrophages and DCs can be found in Supplementary Note 1.
Gautier E.L., Shay T., Miller J., Greter M., Jakubzick C., Ivanov S., Helft J., Chow A., Elpek K.G., Gordonov S., Mazloom A.R., Ma’ayan A., Chua W.J., Hansen T.H., Turley S.J., Merad M, & Randolph G.J. (2012). Gene expression profiles and transcriptional regulatory pathways underlying mouse tissue macrophage identity and diversity. Nature immunology, 13(11), 1118-1128.
Publication 2012
Antibodies Brain Cells Dental Pulp isolation ITGAM protein, human Liberase Lung Macrophage Macrophages, Alveolar Macrophages, Peritoneal Microglia Mus NRG1 protein, human Percoll Peritoneal Lavage Population Group Spleen Tissue Procurement Tissues trizol
5
Immune Cell Isolation from Donor Tissues
Tissue collection occurred after the donor organs were flushed with cold
preservation solution and clinical procurement was completed. Tissues were
processed within 2–4hrs of organ procurement resulting in high yields of
live immune cells (17 (link), 19 (link), 23 (link)) (see online
methods). For blood samples, lymphocytes were isolated by
centrifugation through lymphocyte separation medium (Corning); monocytes and
neutrophils were isolated using whole blood lysis techniques with ACK lysing
buffer (Lonza, Walkersville, Md.).
Carpenter D.J., Granot T., Matsuoka N., Senda T., Kumar B.V., Thome J.J., Gordon C.L., Miron M., Weiner J., Connors T., Lerner H., Friedman A., Kato T., Griesemer A.D, & Farber D.L. (2017). Human immunology studies using organ donors: impact of clinical variations on immune parameters in tissues and circulation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 18(1), 74-88.
Publication 2017
Blood Cells Donor, Organ Lymphocyte Monocytes Tissue Procurement

Most recents protocols related to «Tissue Procurement»

1
Kidney Biopsy Tissue Profiling for T2D

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
American Indian or Alaska Native Biopsy Diabetes Mellitus Digestive System Ethics Committees, Research Gene Chips Gene Expression Genome, Human Genotype Kidney Kidney Diseases Kidney Glomerulus Living Donors Microarray Analysis Microdissection Tissue Procurement Tissues Vulnerable Populations
2
IPF Lung Tissue Procurement and Use
Deidentified patient samples were obtained by our tissue procurement service (Bionet) under a waiver of informed consent from the University of Minnesota IRB (no. 1504M68341). Fresh IPF lungs were obtained at the time of lung transplantation, and control lung tissue was obtained by VATS biopsy or lobectomy. Animal protocols were approved and conducted in accordance with the University of Minnesota IACUC regulations (approval no. 1706-34890A).
Yang L., Gilbertsen A., Xia H., Benyumov A., Smith K., Herrera J., Racila E., Bitterman P.B, & Henke C.A. (2023). Hypoxia enhances IPF mesenchymal progenitor cell fibrogenicity via the lactate/GPR81/HIF1α pathway. JCI Insight, 8(4), e163820.
Full text: Click here
Publication 2023
Animals Biopsy Institutional Animal Care and Use Committees Lung Lung Transplantation Patients Thoracic Surgery, Video-Assisted Tissue Procurement Tissues
3
Cardiovascular Tissue Banking Protocols
BST is a public agency under the Catalan Ministery of Health. Its mission is to guarantee the supply and proper use of human blood and tissues in Catalonia, following applicable regulation (Directive 2004/23/EC 2004 ; Commission directive 2006 /17/EC; Commission Directive 2006 /86/EC) and good practices (EDQM; Council of Europe 2019 ).
The BTB is subjected to Spanish Legislation (RD-L 9/2014 2014 ) and European Directives on the use of tissues and cells of human origin for therapeutic purposes (EU 2004/23/EC). The BTB’s quality standards are in accordance with European Directives 2006/17/EC and 2006/86/EC, as well as the Guide to the Quality and Safety of Tissues and Cells for Human application (EDQM, 4th Ed.).
The BTB is a multi-tissue bank with two main working areas. On one hand, there is a DC, which is responsible of (1) complete donor screening (attending potential donor calls from any hospital in Catalonia or Spain, consent interviews with the families, judicial consent if applies and donor testing), (2) management of the retrieval teams, and (3) tissue procurement. On the other hand, there is a tissue establishment (TE), which is responsible for preparing, evaluating, storing and distributing tissues for transplantation.
DC is composed by medical and nursing staff and also includes a multi-tissue retrieval team, which is always composed by a doctor (team leader) and two technician that can be nurses or professionals with other qualifications in the health field. In the TE, the people responsible for the preparation and cryopreservation of CV tissue are technicians specialised in tissue dissection and evaluation (CV but also skin, amniotic membrane, ocular and muskulosqueletal tissue); in addition, there is also a research team. The BTB team also includes quality assurance and quality control staff. Finally, in the TE there is a tissue allocation team in charge of receiving all the requests from transplant centres as well as tissue shipment arrangements. To guaranty process traceability it is required an implant confirmation form and the information of the final use of the tissue.
Castells-Sala C., Pérez M.L., Agustí E., Aiti A., Tarragona E., Navarro A., Tabera J., Fariñas O., Pomar J.L, & Vilarrodona A. (2023). Last twenty-years activity of cardiovascular tissue banking in Barcelona. Cell and Tissue Banking.
Full text: Click here
Publication 2023
Amnion BLOOD Cells Cryopreservation Dissection Europeans Grafts Hispanic or Latino Homo sapiens Nurses Nursing Staff Physicians Safety Skin Therapeutics Tissue Donors Tissue Procurement Tissues Tissue Transplantation Vision
4
Quantitative RT-PCR Analysis of Gene Expression
Tissue procurement has already been described [41 (link)]. Briefly, for the extraction of RNA, one snap-frozen cerebrum hemisphere per animal was homogenized in peqGOLD RNAPure™ (PEQLAB Biotechnologie, Erlangen, Germany), and the total RNA was isolated per the product protocol. Then 2 µg of RNA was DNase treated and reverse transcribed. Each cDNA sample was diluted 10 times with nuclease-free water and was stored at −20 °C.
PCR was performed with qPCR BIO Mix Hi-ROX (NIPPON Genetics Europe, Düren, Germany). The amplification program was as follows: 50° for 2 min, 94 °C for 2 min, 40 cycles at 94 °C for 5 s, and 62 °C for 25 s. Reactions for each sample were carried out in triplicate in 96-well plates. The detection of PCR products was performed in triplicate in 11 μL reaction mix, each containing 5 μL of qPCR mastermix, 2.5 μL of 1.25 μM of each oligonucleotide primer, 0.5 μL of 5 μM of probe, and 3 μL of cDNA template (17 ng). Probes were labeled with the fluorescent reporter 6-carboxy-fluorescein (6-FAM) at the 5′ end and the fluorescent quencher carboxytetramethylrhodamine (TAMRA) at the 3′ end (BioTez Berlin Buch GmbH, Berlin, Germany). The PCR products of target genes were quantified in real time with the sequences summarized in Table 1. The abundance of each gene was determined relative to the hypoxanthine-guanine phosphoribosyl-transferase (HPRT). The expression of target genes was analyzed with the StepOnePlus real-time PCR system (Applied Biosystems, Carlsbad, CA, USA) according to the 2−ΔΔCT method [45 (link)].
Heise J., Schmitz T., Bührer C, & Endesfelder S. (2023). Protective Effects of Early Caffeine Administration in Hyperoxia-Induced Neurotoxicity in the Juvenile Rat. Antioxidants, 12(2), 295.
Full text: Click here
Publication 2023
Animals carboxyfluorescein Cerebral Hemispheres Deoxyribonuclease I DNA, Complementary Freezing Gene Expression Genes Hypoxanthine Phosphoribosyltransferase Oligonucleotide Primers Proteins Tissue Procurement
5
Single-Cell Analysis of Solid Tumors
Thirty-six patients with PDA (n=20), HCC (n=11), or intrahepatic CCA (n=5), identified at our multidisciplinary pancreatic and liver tumor programs underwent informed consent for tissue procurement and clinical-pathological demographic information under an IRB approved protocol. All samples were confirmed to be malignant by pathologist review. Subjects who were being considered for surgical resection were eligible as were PDA patients undergoing biopsy in preparation for either standard of care neoadjuvant chemotherapy or for chemotherapy as primary treatment. Biopsies of PDA patients were performed of either primary pancreatic tumors or liver metastases by EUS or percutaneous radiographic guidance, respectively (2-4 18-gauge cores). All HCC specimens were collected from surgical resection. CCA specimens were collected from either biopsy (n=2) or surgical resection (n=3). Freshly procured tissue was immediately placed in tissue storage media at 4°C, which was processed into small pieces with a scalpel and enzymatically digested into single cell suspensions in gentleMACS C tubes with Human Tissue Dissociation Kit by gentleMACS Octo Dissociator with Heaters (Miltenyi Biotec) for 30 minutes, then filtered through a 40 uM strainer. Cells were pelleted and freshly stained with antibodies for flow cytometry analysis within two hours from time of sample acquisition.
Wan S., Zhao E., Freeman D., Weissinger D., Krantz B.A., Werba G., Khanna L.G., Siolas D., Oberstein P.E., Chattopadhyay P.K., Simeone D.M, & Welling T.H. (2023). Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies. Frontiers in Immunology, 14, 1067352.
Full text: Click here
Publication 2023
Antibodies Biopsy Cells Flow Cytometry Homo sapiens Liver Neoadjuvant Chemotherapy Neoplasm Metastasis Neoplasms, Liver Operative Surgical Procedures Pancreas Pancreatic Neoplasm Pathologists Patients Pharmacotherapy Strains Tissue Procurement Tissues X-Rays, Diagnostic

Top products related to «Tissue Procurement»

1
Tissue tek by Sakura Finetek
Sourced in United States, Japan, Netherlands, Germany, United Kingdom, France, Spain
Tissue-Tek is a line of laboratory equipment designed for the processing and embedding of tissue samples. It provides a comprehensive solution for tissue preparation, enabling consistent and reliable results for various clinical and research applications.
2
Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
3
Fetal calf serum (fcs) by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, France, China, Switzerland, Australia, Austria, Italy, Japan, Canada, Belgium, Brazil, Spain, New Zealand, Netherlands, Denmark, Israel, Sweden, Ireland, Poland, Holy See (Vatican City State), Bulgaria, Argentina, Hungary, Macao
Fetal calf serum is a nutrient-rich cell culture supplement derived from the blood of bovine fetuses. It provides a complex mixture of proteins, growth factors, and other components that support the growth and proliferation of cells in in vitro cell culture systems.
4
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
5
Pentobarbital by Pfizer
Sourced in United States
Pentobarbital is a barbiturate drug that acts as a central nervous system depressant. It is used as a sedative-hypnotic drug and has applications in various laboratory settings.
6
Gentlemacs dissociator by Miltenyi Biotec
Sourced in Germany, United States, United Kingdom, France, Australia, Italy, Japan, Canada, Sweden, Spain, China, Switzerland
The GentleMACS Dissociator is a laboratory instrument designed for the automated dissociation and homogenization of tissue samples. It utilizes pre-programmed protocols to efficiently process a variety of sample types, including tissues, cell suspensions, and other biological materials, into single-cell suspensions suitable for further analysis or downstream applications.
7
Trizol reagent by Thermo Fisher Scientific
Sourced in United States, China, Japan, Germany, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Netherlands, Belgium, Lithuania, Denmark, Singapore, New Zealand, India, Brazil, Argentina, Sweden, Norway, Austria, Poland, Finland, Israel, Hong Kong, Cameroon, Sao Tome and Principe, Macao, Taiwan, Province of China, Thailand
TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components designed for the isolation of total RNA, DNA, and proteins from a variety of biological samples. The reagent maintains the integrity of the RNA while disrupting cells and dissolving cell components.
8
Phosphate buffered saline (pbs) by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Belgium, Italy, Switzerland, Ireland, Spain, Netherlands, Poland, Denmark, India, Norway, Austria, Sweden, Macao, Singapore, Israel, Sao Tome and Principe, New Zealand, Hong Kong, Portugal, Panama, Malaysia, Lithuania, Brazil
Phosphate-buffered saline (PBS) is a widely used buffer solution in biological research and laboratory procedures. It is a balanced salt solution that maintains a physiological pH and osmolarity, making it suitable for a variety of applications. PBS is primarily used to maintain the viability and integrity of cells, tissues, and other biological samples during various experimental protocols.
9
Ficoll paque by GE Healthcare
Sourced in Sweden, United States, United Kingdom, Germany, Canada, Belgium, Italy, Australia, Austria, France, Japan, Singapore, Denmark
Ficoll-Paque is a density gradient medium used for the isolation and purification of cells, such as mononuclear cells, from whole blood or other biological samples. It is designed to separate different cell types based on their density differences during centrifugation.
10
Ficoll paque plus by GE Healthcare
Sourced in Sweden, United States, United Kingdom, Germany, Canada, Japan, Italy, China, France, Australia, Belgium, Austria, Spain, Switzerland, Norway, New Zealand, Denmark, Finland, Georgia
Ficoll-Paque PLUS is a sterile, ready-to-use medium for the isolation of mononuclear cells from blood or bone marrow by density gradient centrifugation. It is a polysucrose and sodium diatrizoate solution with a density of 1.077 g/mL.

More about "Tissue Procurement"

Tissue Acquisition, Tissue Harvesting, Tissue Sampling, Biological Sample Collection, Tissue Isolation, Tissue Excision, Tissue Extraction, Tissue Explantation, Tissue Dissociation, Tissue Disaggregation, Tissue Dissection, Tissue Excision, Tissue Digestion, Tissue Homogenization, Tissue Fractionation, Tissue Separation, Tissue Culture, Tissue Engineering, Tissue Banking, Tissue Repository, Biospecimen Collection, Biospecimen Procurement, Biospecimen Sourcing, Biospecimen Management, Biospecimen Handling, Biospecimen Storage, Biospecimen Preservation, Biospecimen Archiving, Biorepository, Bioresource, Biopsy, Explant, Xenograft, Allograft, Autograft, Organ Donation, Organ Transplantation, Cell Line Derivation, Primary Cell Isolation, Cell Culture, Cell Expansion, Cell Immortalization, Tissue-Tek, DMEM, Fetal Calf Serum, FBS, Pentobarbital, GentleMACS Dissociator, TRIzol Reagent, PBS, Ficoll-Paque, Ficoll-Paque PLUS, Tissue Viability, Tissue Integrity, Tissue Quality Control, Tissue Traceability, Tissue Regulation, Tissue Ethics, Tissue Consent, Tissue Donation, Tissue Transplantation, Tissue Research, Tissue Therapeutics, Tissue Engineering, Tissue Regeneration, Tissue Repair, Tissue Reconstruction, Tissue Replacement, Tissue Grafting, Tissue Implantation, Tissue Scaffolding, Tissue Engineering Scaffold, Tissue Culture Medium, Cell Culture Medium, Cell Culture Supplement, Cell Culture Reagent, Tissue Processing, Tissue Preservation, Tissue Cryopreservation, Tissue Fixation, Tissue Embedding, Tissue Sectioning, Tissue Staining, Tissue Imaging, Tissue Analysis, Tissue Characterization, Tissue Phenotyping, Tissue Genotyping, Tissue Biomarker, Tissue Omics, Tissue Bioinformatics, Tissue Biomarker Discovery, Tissue Microarray, Tissue Biobank, Tissue Repository, Tissue Inventory, Tissue Traceability, Tissue Logistics, Tissue Supply Chain, Tissue Procurement Process, Tissue Procurement Protocols, Tissue Procurement Guidelines, Tissue Procurement Regulations, Tissue Procurement Best Practices, Tissue Procurement Quality Control, Tissue Procurement Optimization, Tissue Procurement Automation, Tissue Procurement Efficiency, Tissue Procurement Data Analytics, Tissue Procurement AI, Tissue Procurement Reproducibility, Tissue Procurement Research Accuracy.